|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||5.25 - 5.50|
|52 Week Range||3.60 - 6.15|
|PE Ratio (TTM)||N/A|
|Earnings Date||Apr 25, 2018 - Apr 30, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||7.20|
The shares of Cogentix Medical (CGNT) rose over 13% yesterday after reports surfaced that the company is going to be acquired by Laborie Medical Technologies.
In 2Q18, Accuray’s (ARAY) net revenues were $100.3 million compared with $87.5 million in 2Q17. Its total revenues come from product sales and services provided. Product sales grew from $35.3 million in 2Q17 to $47.1 million in 2Q18.
To increase physician adoption and patient awareness of its systems, Accuray (ARAY) holds and sponsors symposia and educational meetings and educates clinicians about its systems. Accuray focuses on innovation through clinical development and collaboration and seeks constructive feedback from its system users to enhance the company’s product offerings. Accuray endeavors to expand sales in international markets. According to the World Health Organization (or WHO), cancer is the second-leading cause of death worldwide.
Accuray (ARAY) designs, develops, and commercializes advanced radiosurgery and radiation therapy systems for the treatment of tumors. Accuray’s technologies include the CyberKnife and Tomo Theory systems, which deliver radiosurgery, stereotactic body radiation therapy, and adaptive radiation therapy. In February 2018, three of the seven analysts covering Accuray have given the stock a “buy” or higher rating.
Accuray’s (ARAY) CyberKnife systems are robotic systems that treat cancerous tumors through the delivery of radiosurgery. Accuray’s Tomo therapy systems are versatile radiation therapy systems that are used for treating a wide range of cancer types. Based on a CT scanner platform, the Tomo therapy systems provide continuous delivery of radiation from 360 degrees around the patient or from beam angles specified by the clinician.
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
SUNNYVALE, Calif. , Feb. 15, 2018 /PRNewswire/ -- Accuray Incorporated (NASDAQ: ARAY) announced today that the company will present at the 2018 RBC Capital Markets Global Healthcare Conference at the Lotte ...
NEW YORK, Feb. 13, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Accuray ...
SUNNYVALE, Calif., Feb. 5, 2018 /PRNewswire/ -- Accuray Incorporated (ARAY) announced today it has retired all February 2018 convertible notes, including $13 million aggregate principal amount of its 3.50% convertible senior notes and $27 million aggregate principal amount of its 3.50% Series A convertible senior notes both due February 1, 2018. Accuray successfully entered into exchange agreements with the holders of the 3.50% convertible senior notes allowing the Company to settle the $13 million outstanding principal amount and accrued interest in cash and approximately 0.3 million shares of its common stock. After giving effect to the settlement of the exchange agreements, no 3.50% convertible senior notes will remain outstanding.
Pacific Biosciences' (PACB) consumable revenue platform proves a vital growth-driver in Q4. Sales momentum in China remains robust.
Quest Diagnostics' (DGX) year-over-year revenue improvement in Q4 came on the back of successful execution of its two-point strategy of accelerating growth and driving operational excellence.
Strong Performance in Distribution Solutions segment drives McKesson (MCK) in Q3. An impressive FY18 outlook instills investor's optimism.
Sirtex Medical Systems is an Australia-based life sciences company with a presence around the globe. The company is focused on interventional oncology therapies and is a global leader in radioembolization. Radioembolization is a minimally invasive therapy for the treatment of liver cancer.
Zacks.com highlights: Accuray, Berkshire Hills Bancorp, A. Schulman, Sysco and Tailored Brands
Thermo Fisher (TMO) registers a solid international performance in Q4 with strong year-over-year growth in the Asia-Pacific and the emerging markets of China, South Korea and the Middle East.